MIGHTY initiative unites top academic and industry partners to develop a rapid, AI-powered platform for precision phage ...

Researchers from the Carl R. Woese Institute for Genomic Biology at the University of Illinois Urbana-Champaign will partner ...

The U.S. government has agreed to loan privately-held biotechnology firm Ginkgo Bioworks $1.1 billion for COVID-19 testing and the production of raw materials for therapies that may help address ...

Ginkgo Bioworks Holdings has seen its consensus analyst price target rise from $11.33 per share to $12.00 per share. This reflects a modest but noteworthy vote of confidence from the market. The ...

Ginkgo Bioworks Holdings, Inc. (DNA) reached $15.24 at the closing of the latest trading day, reflecting a -5.28% change compared to its last close.

Recursion Pharmaceuticals' stock rises on heavy trading volume, with investors eyeing its AI-designed cancer drug REC-3565 ...

Ginkgo Bioworks Holdings, Inc. (DNA) concluded the recent trading session at $16.14, signifying a +1.06% move from its prior day's close.

The teams are developing over-the-counter, synthetic multi-cancer early detection tests to identify more than 30 stage I solid tumors using breath or urine samples.

A Multi-Party Team represented by Carnegie Mellon University researchers and private industry partners has secured an award of up to $26.7 million from the Advanced Research Projects Agency for Health ...

E. coli is the field's main "workhorse" says Prof Wallace, who has also genetically engineered it in the lab to turn plastic ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An announcement from Ginkgo Bioworks ...

OMERS ADMINISTRATION Corp grew its stake in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Free Report) by 14.1% during the 1st quarter, according to the company in its most recent 13F filing with the ...